The antitumor efficacy of cytotoxic drugs is potentiated by treatment with PNU 145156E, a growth-factor-complexing molecule

Francesco Sola, L. Capolongo, Donatella Moneta, Paolo Ubezio, Maria Grandi

Research output: Contribution to journalArticle

Abstract

PNU 145156E (formerly FCE 26644) is a noncytotoxic molecule whose antitumor activity is exerted through the formation of a reversible complex with growth/angiogenic factors, thus inhibiting their induction of angiogenesis. We studied in vitro and in vivo the activity of PNU145156E in combination with the four cytotoxic drugs doxorubicin, cyclophosphamide, methoxymorpholinyldoxorubicin (MMDX, FCE 23762, PNU152243), and 9- aminocamptothecin against M5076 murine reticulosarcoma. In vitro, PNU 145156E did not modify the cytotoxicity of the four drugs or the cell-cycle block induced by doxorubicin. In vivo, at the optimal dose of each compound, the antitumor activity was significantly increased in all combinations, with no associated increase in general toxicity being observed. In healthy mice treated with cyclophosphamide or doxorubicin the association with PNU145156E did not enhance the myelotoxic effect induced by the two cytotoxics. These results indicate that two drugs affecting solid tumor growth through two different mechanisms growth factor blockage and cell proliferation - can be combined, resulting in increased antitumor efficacy with no additive toxicity.

Original languageEnglish
Pages (from-to)241-246
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume43
Issue number3
DOIs
Publication statusPublished - 1999

Fingerprint

Doxorubicin
Intercellular Signaling Peptides and Proteins
9-aminocamptothecin
Cyclophosphamide
Molecules
Toxicity
Pharmaceutical Preparations
Angiogenesis Inducing Agents
Cell proliferation
Cytotoxicity
Non-Hodgkin's Lymphoma
Tumors
Cell Cycle
Cells
Cell Proliferation
Growth
FCE 26644
Neoplasms
methoxy-morpholinyl-doxorubicin
In Vitro Techniques

Keywords

  • Angiogenesis
  • Growth factors
  • Suramin

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

The antitumor efficacy of cytotoxic drugs is potentiated by treatment with PNU 145156E, a growth-factor-complexing molecule. / Sola, Francesco; Capolongo, L.; Moneta, Donatella; Ubezio, Paolo; Grandi, Maria.

In: Cancer Chemotherapy and Pharmacology, Vol. 43, No. 3, 1999, p. 241-246.

Research output: Contribution to journalArticle

@article{7780e8d7c59943e1a4862e6eb3eab92b,
title = "The antitumor efficacy of cytotoxic drugs is potentiated by treatment with PNU 145156E, a growth-factor-complexing molecule",
abstract = "PNU 145156E (formerly FCE 26644) is a noncytotoxic molecule whose antitumor activity is exerted through the formation of a reversible complex with growth/angiogenic factors, thus inhibiting their induction of angiogenesis. We studied in vitro and in vivo the activity of PNU145156E in combination with the four cytotoxic drugs doxorubicin, cyclophosphamide, methoxymorpholinyldoxorubicin (MMDX, FCE 23762, PNU152243), and 9- aminocamptothecin against M5076 murine reticulosarcoma. In vitro, PNU 145156E did not modify the cytotoxicity of the four drugs or the cell-cycle block induced by doxorubicin. In vivo, at the optimal dose of each compound, the antitumor activity was significantly increased in all combinations, with no associated increase in general toxicity being observed. In healthy mice treated with cyclophosphamide or doxorubicin the association with PNU145156E did not enhance the myelotoxic effect induced by the two cytotoxics. These results indicate that two drugs affecting solid tumor growth through two different mechanisms growth factor blockage and cell proliferation - can be combined, resulting in increased antitumor efficacy with no additive toxicity.",
keywords = "Angiogenesis, Growth factors, Suramin",
author = "Francesco Sola and L. Capolongo and Donatella Moneta and Paolo Ubezio and Maria Grandi",
year = "1999",
doi = "10.1007/s002800050890",
language = "English",
volume = "43",
pages = "241--246",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - The antitumor efficacy of cytotoxic drugs is potentiated by treatment with PNU 145156E, a growth-factor-complexing molecule

AU - Sola, Francesco

AU - Capolongo, L.

AU - Moneta, Donatella

AU - Ubezio, Paolo

AU - Grandi, Maria

PY - 1999

Y1 - 1999

N2 - PNU 145156E (formerly FCE 26644) is a noncytotoxic molecule whose antitumor activity is exerted through the formation of a reversible complex with growth/angiogenic factors, thus inhibiting their induction of angiogenesis. We studied in vitro and in vivo the activity of PNU145156E in combination with the four cytotoxic drugs doxorubicin, cyclophosphamide, methoxymorpholinyldoxorubicin (MMDX, FCE 23762, PNU152243), and 9- aminocamptothecin against M5076 murine reticulosarcoma. In vitro, PNU 145156E did not modify the cytotoxicity of the four drugs or the cell-cycle block induced by doxorubicin. In vivo, at the optimal dose of each compound, the antitumor activity was significantly increased in all combinations, with no associated increase in general toxicity being observed. In healthy mice treated with cyclophosphamide or doxorubicin the association with PNU145156E did not enhance the myelotoxic effect induced by the two cytotoxics. These results indicate that two drugs affecting solid tumor growth through two different mechanisms growth factor blockage and cell proliferation - can be combined, resulting in increased antitumor efficacy with no additive toxicity.

AB - PNU 145156E (formerly FCE 26644) is a noncytotoxic molecule whose antitumor activity is exerted through the formation of a reversible complex with growth/angiogenic factors, thus inhibiting their induction of angiogenesis. We studied in vitro and in vivo the activity of PNU145156E in combination with the four cytotoxic drugs doxorubicin, cyclophosphamide, methoxymorpholinyldoxorubicin (MMDX, FCE 23762, PNU152243), and 9- aminocamptothecin against M5076 murine reticulosarcoma. In vitro, PNU 145156E did not modify the cytotoxicity of the four drugs or the cell-cycle block induced by doxorubicin. In vivo, at the optimal dose of each compound, the antitumor activity was significantly increased in all combinations, with no associated increase in general toxicity being observed. In healthy mice treated with cyclophosphamide or doxorubicin the association with PNU145156E did not enhance the myelotoxic effect induced by the two cytotoxics. These results indicate that two drugs affecting solid tumor growth through two different mechanisms growth factor blockage and cell proliferation - can be combined, resulting in increased antitumor efficacy with no additive toxicity.

KW - Angiogenesis

KW - Growth factors

KW - Suramin

UR - http://www.scopus.com/inward/record.url?scp=0032922263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032922263&partnerID=8YFLogxK

U2 - 10.1007/s002800050890

DO - 10.1007/s002800050890

M3 - Article

C2 - 9923555

AN - SCOPUS:0032922263

VL - 43

SP - 241

EP - 246

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -